scispace - formally typeset
T

Tarek M. Fahmy

Researcher at Yale University

Publications -  165
Citations -  11864

Tarek M. Fahmy is an academic researcher from Yale University. The author has contributed to research in topics: T cell & Antigen. The author has an hindex of 49, co-authored 164 publications receiving 10405 citations. Previous affiliations of Tarek M. Fahmy include Johns Hopkins University & DuPont.

Papers
More filters
Journal ArticleDOI

Label-free immunodetection with CMOS-compatible semiconducting nanowires

TL;DR: This work reports an approach that uses complementary metal oxide semiconductor (CMOS) field effect transistor compatible technology and hence demonstrates the specific label-free detection of below 100 femtomolar concentrations of antibodies as well as real-time monitoring of the cellular immune response.
Journal ArticleDOI

The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome–mediated inflammatory disease

TL;DR: In vivo, BHB or a ketogenic diet attenuates caspase-1 activation and IL-1β secretion in mouse models of NLRP3-mediated diseases such as Muckle–Wells syndrome, familial cold autoinflammatory syndrome and urate crystal–induced peritonitis and the findings suggest that the anti-inflammatory effects of caloric restriction or ketogenic diets may be linked to BHB-mediated inhibition of theNLRP3 inflammasome.
Journal ArticleDOI

Importance of the Debye screening length on nanowire field effect transistor sensors.

TL;DR: The appropriate conditions under which the selective binding of macromolecules is accurately sensed with NW-FET sensors are shown.
Journal ArticleDOI

Label-free biomarker detection from whole blood.

TL;DR: This work shows specific and quantitative detection of two model cancer antigens from a 10 uL sample of whole blood in less than 20 minutes and reduces its minimum required sensitivity by effectively pre-concentrating the biomarkers.
Journal ArticleDOI

Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy

TL;DR: N nanoscale liposomal polymeric gels (nanolipogels; nLGs) of drug-complexed cyclodextrins and cytokine-encapsulating biodegradable polymers that can deliver small hydrophobic molecular inhibitors and water-soluble protein cytokines in a sustained fashion to the tumour microenvironment significantly delayed tumour growth and increased survival of tumour-bearing mice.